View in EDS HTML Full Text PDF Full Text

Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study.

Saved in:
Bibliographic Details
Title: Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study.
Authors: Fautrel B; Sorbonne University, AP-HP, Hôpital de La Pitié-Salpêtrière, INSERM UMRS 1136, Paris, France., Bouhnik Y; Paris IBD Center, Groupe hospitalier privé Ambroise Paré-Hartmann, Neuilly-sur-Seine, France., Salliot C; Rheumatology Department, Centre Hospitalier Universitaire d'Orléans, Orléans, France., Carbonnel F; Hôpital Bicêtre, AP-HP, Le Kremlin Bicêtre, France., Fumery M; Département de Gastroentérologie, CHU Amiens, Amiens, France., Bernardeau C; Clinique François Chénieux, Limoges, France., Maugars Y; INSERM, UMR 1229, RMeS, Regenerative Medicine and Skeleton, Université de Nantes, ONIRIS, Nantes, France.; Odontology Department, University of Nantes, Nantes, France.; Rheumatology Department, CHU de Nantes, Nantes, France., Flamant M; Département de Gastroentérologie, Clinique Jules Verne, Nantes, France., Coury F; Rheumatology Department, Lyon Sud Hospital, Hospices Civils de Lyon, University of Lyon, Lyon, France.; INSERM UMR 1033, Lyon Immunopathology Federation, Lyon, France., Braithwaite B; Sanoïa e-Health Services, 188 av 2nd Division Blindée, 13420, Gémenos, France. bbraithwaite@sanoia.com., Hateb S; Biogen France SAS, Gastroenterology and Rhumatologie, Biosimilars, Courbevoie, France., Addison J; Biogen IDEC, Clinical Research, Biosimilars, Maidenhead, UK.
Corporate Authors: PERFUSE investigators
Source: Drugs - real world outcomes [Drugs Real World Outcomes] 2024 Dec; Vol. 11 (4), pp. 573-591. Date of Electronic Publication: 2024 Oct 10.
Publication Type: Journal Article
Journal Info: Publisher: Springer International Publishing Country of Publication: Switzerland NLM ID: 101658456 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2199-1154 (Print) Linking ISSN: 21989788 NLM ISO Abbreviation: Drugs Real World Outcomes Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39384685
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Fautrel+B%22">Fautrel B</searchLink>; Sorbonne University, AP-HP, Hôpital de La Pitié-Salpêtrière, INSERM UMRS 1136, Paris, France.<br /><searchLink fieldCode="AU" term="%22Bouhnik+Y%22">Bouhnik Y</searchLink>; Paris IBD Center, Groupe hospitalier privé Ambroise Paré-Hartmann, Neuilly-sur-Seine, France.<br /><searchLink fieldCode="AU" term="%22Salliot+C%22">Salliot C</searchLink>; Rheumatology Department, Centre Hospitalier Universitaire d'Orléans, Orléans, France.<br /><searchLink fieldCode="AU" term="%22Carbonnel+F%22">Carbonnel F</searchLink>; Hôpital Bicêtre, AP-HP, Le Kremlin Bicêtre, France.<br /><searchLink fieldCode="AU" term="%22Fumery+M%22">Fumery M</searchLink>; Département de Gastroentérologie, CHU Amiens, Amiens, France.<br /><searchLink fieldCode="AU" term="%22Bernardeau+C%22">Bernardeau C</searchLink>; Clinique François Chénieux, Limoges, France.<br /><searchLink fieldCode="AU" term="%22Maugars+Y%22">Maugars Y</searchLink>; INSERM, UMR 1229, RMeS, Regenerative Medicine and Skeleton, Université de Nantes, ONIRIS, Nantes, France.; Odontology Department, University of Nantes, Nantes, France.; Rheumatology Department, CHU de Nantes, Nantes, France.<br /><searchLink fieldCode="AU" term="%22Flamant+M%22">Flamant M</searchLink>; Département de Gastroentérologie, Clinique Jules Verne, Nantes, France.<br /><searchLink fieldCode="AU" term="%22Coury+F%22">Coury F</searchLink>; Rheumatology Department, Lyon Sud Hospital, Hospices Civils de Lyon, University of Lyon, Lyon, France.; INSERM UMR 1033, Lyon Immunopathology Federation, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Braithwaite+B%22">Braithwaite B</searchLink>; Sanoïa e-Health Services, 188 av 2nd Division Blindée, 13420, Gémenos, France. bbraithwaite@sanoia.com.<br /><searchLink fieldCode="AU" term="%22Hateb+S%22">Hateb S</searchLink>; Biogen France SAS, Gastroenterology and Rhumatologie, Biosimilars, Courbevoie, France.<br /><searchLink fieldCode="AU" term="%22Addison+J%22">Addison J</searchLink>; Biogen IDEC, Clinical Research, Biosimilars, Maidenhead, UK.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22PERFUSE+investigators%22">PERFUSE investigators</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101658456%22">Drugs - real world outcomes</searchLink> [Drugs Real World Outcomes] 2024 Dec; Vol. 11 (4), pp. 573-591. <i>Date of Electronic Publication: </i>2024 Oct 10.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+International+Publishing%22">Springer International Publishing </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101658456 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Print <i>ISSN: </i>2199-1154 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2221989788%22">21989788 </searchLink><i>NLM ISO Abbreviation: </i>Drugs Real World Outcomes <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39384685
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s40801-024-00459-6
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 573
    Titles:
      – TitleFull: Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Fautrel B
      – PersonEntity:
          Name:
            NameFull: Bouhnik Y
      – PersonEntity:
          Name:
            NameFull: Salliot C
      – PersonEntity:
          Name:
            NameFull: Carbonnel F
      – PersonEntity:
          Name:
            NameFull: Fumery M
      – PersonEntity:
          Name:
            NameFull: Bernardeau C
      – PersonEntity:
          Name:
            NameFull: Maugars Y
      – PersonEntity:
          Name:
            NameFull: Flamant M
      – PersonEntity:
          Name:
            NameFull: Coury F
      – PersonEntity:
          Name:
            NameFull: Braithwaite B
      – PersonEntity:
          Name:
            NameFull: Hateb S
      – PersonEntity:
          Name:
            NameFull: Addison J
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2024 Dec
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 2199-1154
          Numbering:
            – Type: volume
              Value: 11
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Drugs - real world outcomes
              Type: main
ResultId 1